Fabre-Kramer Pharmaceuticals
From Wikipedia, the free encyclopedia
Fabre-Kramer Pharmaceuticals is a pharmaceutical company that specializes in the development of psychotropic drugs. Products in their current development pipeline include gepirone and FKB01MD for major depression, gepirone and FKW00GA for social anxiety disorder,[1] gepirone for hypoactive sexual desire disorder, FKF02SC for schizophrenia, and FKK01PD for Parkinson's disease.[2]
 | |
| Company type | S Corporation |
|---|---|
| Industry | Pharmaceuticals |
| Founded | 1992 |
| Headquarters | Houston, Texas |
Key people | Stephen Kramer (CEO) Ed Koehler (Executive Vice President, CFO) |
| Products | Travivo (Gepirone ER), FKB01MD, FKW00GA, FKF02SC, FKK01PD |
| Website | www.fabrekramer.com |
The company has also conducted clinical studies on a gepirone extended release formulation for major depression.[3][4][5]
In 2007, Fabre-Kramer Pharmaceuticals along with GlaxoSmithKline (GSK) received a 'not approvable' letter from the US Food and Drug Administration, for a gepirone extended release drug, an antidepressant treatment for adults.[6]
